Ag0302-Covid‑19
From Handwiki Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | DNA vaccination |
| Clinical data | |
| Routes of administration | Intramuscular, Intradermal[1] |
AG0302-COVID‑19 is a COVID-19 vaccine candidate developed by AnGes Inc.[2][3]This candidate followed a previous one called AG0301-COVID‑19.[4]
References
- ↑ "Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)". United States National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04993586.
- ↑ Study of COVID-19 DNA Vaccine (AG0302-COVID19). United States National Library of Medicine. 3 December 2020. https://clinicaltrials.gov/ct2/show/NCT04527081. Retrieved 11 March 2021.
- ↑ "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". United States National Library of Medicine. https://www.clinicaltrials.gov/ct2/show/NCT04655625.
- ↑ "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". United States National Library of Medicine. 9 July 2020. https://clinicaltrials.gov/ct2/show/NCT04463472.
 |
Categories: [Clinical trials]
↧ Download as ZWI file | Last modified: 01/18/2025 04:11:50 | 4 views
☰ Source: https://handwiki.org/wiki/Medicine:AG0302-COVID‑19 | License: CC BY-SA 3.0
✘
ZWI is not signed. [what is this?]
ZWI viewer
by the 
KSF
KSF